About: BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.04 (-8.16%)
BCTX NASDAQ Briacell Therapeutics Corp
Briacell Therapeutics Corp share price
BCTX price activity
Last Price
$3.040
Change (24hr)
-0.27 USD (8.16%)
Volume
130.63K
Volume (4w avg)
-
Open
$3.35
Day Range
$2.95 - $3.35
Previous Close
$3.31
Last Trade
30 Oct, 8:03 pm GMT+0
Delayed
30 Oct, 8:03 pm GMT+0
BCTX price performance
Delayed
30 Oct, 8:03 pm GMT+0
BCTX Market Signals